News

Alessa Therapeutics Announces IND Clearance to Collaborate with the National Cancer Institute

Alessa Therapeutics, Inc., a clinical-stage drug development company founded by University of California, San Francisco professor Dr. Pamela Munster, announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug application (IND) for Biolen®. Alessa, in...

Thermo Fisher partners with UCSF for early biotech manufacturing

A multimillion-dollar deal between the University of California, San Francisco, and biotech tools giant Thermo Fisher Scientific Inc. will put cell therapies almost literally within reach of UCSF cancer patients, doctors and researchers, as well as companies pursuing one of the hottest areas cancer...

Soteria Launches with $42 Million in Series A Financing

Soteria Biotherapeutics, Inc. a privately-held, immuno-oncology company focused on developing a next generation of switchable bispecific T-cell engagers to treat patients with solid tumor cancers, today announced a $42 million Series A financing led by Roche Venture Fund and 5AM Ventures with...

Journey from Aquarium-to-Bedside to Treat Genetic Epilepsies

Emerging from stealth mode with a pipeline of FDA and EMA Orphan Drug Designation candidates, Epygenix Therapeutics Inc. is poised to become the first biopharmaceutical company to commercialize epilepsy drugs discovered in zebrafish. Epygenix Therapeutics’ six lead drug candidates were identified...

Fortis Therapeutics, a UCSF Founded Startup, Closes $40 Million Series A Financing

Fortis Therapeutics, an immuno-oncology biotech developing FOR46, a novel antibody drug conjugate (ADC) against CD46, today announced the close of a $40 million Series A financing.  “PCF is pleased that the 2017 funding to UCSF for their research on CD46 has been leveraged by Fortis for a...

Immunai Acquires UCSF Startup Dropprint Genomics

Immunai, a New York and Tel Aviv-based biotech company, announced its acquisition of Dropprint Genomics, a San Francisco-based single-cell genomics software company. The Dropprint team co-founders Meena Subramaniam, PhD, and Rachel Gate, PhD, have also joined the Machine Learning and Computational...

NephroSant Announces $16 Million Series A, Led by DaVita Venture Group

NephroSant, a kidney health spin out of UC San Francisco, today announced it has closed its oversubscribed Series A funding round of $16 million.  MORE

Alessa Therapeutics Announces First Australian Patient Enrolled in Biolen-PC Study for New Prostate Cancer Therapy

Founded in 2018 and based on technology developed at the University of California San Francisco, Alessa Therapeutics is developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease. And have announced the enrollment of the first patient in the...

UCSF Technology Sings at San Francisco Opera

In a strange marriage of arts and science, The San Francisco Opera costume department teamed up with doctors from UCSF to create a mask that will allow the company's singers to safely rehearse together -- while greatly diminishing the chances of spreading COVID-19. Video

Sana Announces Closing of Initial Public Offering

Sana Biotechnology, a UCSF startup company focused on creating and delivering engineered cells as medicines, today announced the closing of its upsized initial public offering. The aggregate gross proceeds from the offering were approximately $675.6 million. All of the shares of common stock were...